AMAG Pharmaceuticals (AMAG) +6.8% AH after announcing positive preliminary results for the first...

|About: AMAG Pharmaceuticals, Inc. (AMAG)|By:, SA News Editor

AMAG Pharmaceuticals (AMAG) +6.8% AH after announcing positive preliminary results for the first of 2 Phase III studies for its Feraheme drug. The results suggests Feraheme could be effective in treating iron deficiency regardless of its cause, rather than simply for kidney disease. AMAG plans to submit a supplemental NDA to the FDA that would allow it to expand Feraheme's addressable market.